Vitamin K2 downregulates the expression of fibroblast growth factor receptor 3 in human hepatocellular carcinoma cells

Hepatology Research

Volumn 39, Issue 11, 2009, Pages 1108-1117

  Cao, Ke ^a,b   Liu, Weidong ^a   Nakamura, Hideji ^a   Enomoto, Hirayuki ^a   Yamamoto, Teruhisa ^a   Saito, Masaki ^a   Imanishi, Hiroyasu ^a   Shimomura, Soji ^a   Cao, Peiguo ^b   Nishiguchi, Shuhei ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b THE THIRD XIANGYA HOSPITAL OF CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Fibroblast growth factor receptor 3; Hepatocellular carcinoma; Luciferase assay; Vitamin K2

Indexed keywords

FARNOQUINONE; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 3; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3;

ARTICLE; CANCER INHIBITION; CARCINOMA CELL; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG TARGETING; GENE ACTIVITY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROMOTER REGION; TRANSCRIPTION REGULATION;

EID: 73649132293     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2009.00536.x     Document Type: Article

References (42)

1. Matsumoto K, Okano J, Nagahara T et al. Apoptosis of liver cancer cells by vitamin k2 and enhancement by MEK inhibition. Int J Oncol 2006; 29: 1501-8.
2. Lamson DW, Plaza SM. The anticancer effects of vitamin K. Altern Med Rev 2003; 8: 303-18.
3. Shibayama-Imazu T, Sonoda I, Sakairi S et al. Production of superoxide and dissipation of mitochondrial transmembrane potential by vitamin K2 trigger apoptosis in human ovarian cancer TYK-nu cells. Apoptosis 2006; 11: 1535-43.
4. Habu D, Shiomi S, Tamori A et al. Role of vitamin K2 in the development of hepatocellular carcinoma in women with viral cirrhosis of the liver. JAMA 2004; 292: 358-61.
5. Mizuta T, Ozaki I, Eguchi Y et al. The effect of menatetrenone, a vitamin K2 analog, on disease recurrence and survival in patients with hepatocellular carcinoma after curative treatment: a pilot study. Cancer 2006; 106: 867- 72.
6. Liu W, Nakamura H, Yamamoto T et al. Vitamin K2 inhibits the proliferation of HepG2 cells by up-regulating the transcription of p21 gene. Hepatol Res 2007; 37: 360-5.
7. Ozaki I, Zhang H, Mizuta T et al. Menatetrenone, a vitamin K2 analogue, inhibits hepatocellular carcinoma cell growth by suppressing cyclin D1 expression through inhibition of nuclear factor kappaB activation. Clin Cancer Res 2007; 13: 2236-45.
8. Otsuka M, Kato N, Shao RX et al. Vitamin K2 inhibits the growth and invasiveness of hepatocellular carcinoma cells via protein kinase A activation. Hepatology 2004; 40: 243- 51.
9. Kanamori T, Shimizu M, Okuno M et al. Synergistic growth inhibition by acyclic retinoid and vitamin K2 in human hepatocellular carcinoma cells. Cancer Sci 2007; 98: 431-7.
10. Yoshiji H, Kuriyama S, Noguchi R et al. Amelioration of carcinogenesis and tumor growth in the rat liver by combination of vitamin K2 and angiotensin-converting enzyme inhibitor via anti-angiogenic activities. Oncol Rep 2006; 15: 155-9.
11. Qiu WH, Zhou BS, Chu PG et al. Over-expression of fibroblast growth factor receptor 3 in human hepatocellular carcinoma. World J Gastroenterol 2005; 11: 5266- 72.
12. Shao RX, Otsuka M, Kato N et al. Acyclic retinoid inhibits human hepatoma cell growth by suppressing fibroblast growth factor-mediated signaling pathways. Gastroenterology 2005; 128: 86-95.
13. Bernard-Pierrot I, Brams A, Dunois-Lardé C et al. Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b. Carcinogenesis 2006; 27: 740-7.
14. Eswarakumar VP, Lax I, Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 2005; 16: 139-49.
15. Itoh N, Ornitz DM. Evolution of the Fgf and Fgfr gene families. Trends Genet 2004; 20: 563-9.
16. Masih-Khan E, Trudel S, Heise C et al. MIP-1alpha (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myeloma. Blood 2006; 108: 3465-71.
17. Rotterud R, Fossa SD, Nesland JM. Protein networking in bladder cancer: immunoreactivity for FGFR3, EGFR, ERBB2, KAI1, PTEN, and RAS in normal and malignant urothelium. Histol Histopathol 2007; 22: 349-63.
18. Gomez-Roman JJ, Saenz P, Molina M et al. Fibroblast growth factor receptor 3 is overexpressed in urinary tract carcinomas and modulates the neoplastic cell growth. Clin Cancer Res 2005; 11: 459-65.
19. Kanamori T, Shimizu M, Okuno M et al. Synergistic growth inhibition by acyclic retinoid and vitamin K2 in human hepatocellular carcinoma cells. Cancer Sci 2007; 98: 431-7.
20. St Bernard R, Zheng L, Liu W et al. Fibroblast growth factor receptors as molecular targets in thyroid carcinoma. Endocrinology 2005; 146: 1145-53.
21. Nair S, Watts S, Flood L. Fibroblast growth factor receptor expression in aural polyps: predictor of cholesteatoma? J Laryngol Otol 2004; 118: 338-42.
22. Estes NR 2nd, Thottassery JV, Kern FG. siRNA mediated knockdown of fibroblast growth factor receptors 1 or 3 inhibits FGF-induced anchorage-independent clonogenicity but does not affect MAPK activation. Oncol Rep 2006; 15: 1407-16.
23. Ogasawara S, Yano H, Iemura A et al. Expressions of basic fibroblast growth factor and its receptors and their relationship to proliferation of human hepatocellular carcinoma cell lines. Hepatology 1996; 24: 198-205.
24. Huang X, Yu C, Jin C et al. Ectopic activity of fibroblast growth factor receptor 1 in hepatocytes accelerates hepatocarcinogenesis by driving proliferation and vascular endothelial growth factor-induced angiogenesis. Cancer Res 2006; 66: 1481-90.
25. Prestridge DS. Predicting Pol II promoter sequences using transcription factor binding sites. J Mol Biol 1995; 249: 923-32.
26. McEwen DG, Ornitz DM. Regulation of the fibroblast growth factor receptor 3 promoter and intron I enhancer by Sp1 family transcription factors. J Biol Chem 1998; 273: 5349-57.
27. McEwen DG, Green RP, Naski MC, Towler DA, Ornitz DM. Fibroblast growth factor receptor 3 gene transcription is suppressed by cyclic adenosine 3′,5′-monophosphate. Identification of a chondrocytic regulatory element. J Biol Chem 1999; 274: 30934-42.
28. Reinhold MI, McEwen DG, Naski MC. Fibroblast growth factor receptor 3 gene: regulation by serum response factor. Mol Endocrinol 2004; 18: 241-51.
29. Liu L, Cao Y, Chen C et al. Sorafenib blocks the RAF/MEK/ ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006; 66: 11851-8.
30. Martinez-Torrecuadrada J, Cifuentes G, Lopez-Serra P et al. Targeting the extracellular domain of fibroblast growth factor receptor 3 with human single-chain Fv antibodies inhibits bladder carcinoma cell line proliferation. Clin Cancer Res 2005; 11: 6280-90.
31. Trudel S, Stewart AK, Rom E et al. The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells. Blood 2006; 107: 4039-46.
32. Qian S, Somlo G, Zhou B et al. Ribozyme cleavage leads to decreased expression of fibroblast growth factor receptor 3 in human multiple myeloma cells, which is associated with apoptosis and downregulation of vascular endothelial growth factor. Oligonucleotides 2005; 15: 1-11.
33. Zhu L, Somlo G, Zhou B et al. Fibroblast growth factor receptor 3 inhibition by short hairpin RNAs leads to apoptosis in multiple myeloma. Mol Cancer Ther 2005; 4: 787-98.
34. Trudel S, Li ZH, Wei E et al. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood 2005; 105: 2941-8.
35. Chen J, Lee BH, Williams IR et al. FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies. Oncogene 2005; 24: 8259-67.
36. Trudel S, Ely S, Farooqi Y et al. Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma. Blood 2004; 103: 3521-8.
37. Karoui M, Hofmann-Radvanyi H, Zimmermann U et al. No evidence of somatic FGFR3 mutation in various types of carcinoma. Oncogene 2001; 20: 5059-61.
38. Tomlinson DC, Baldo O, Harnden P et al. FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J Pathol 2007; 213: 91-8.
39. Rosty C, Aubriot MH, Cappellen D et al. Clinical and biological characteristics of cervical neoplasias with FGFR3 mutation. Mol Cancer 2005; 4: 15.
40. L'Hôte CG, Knowles MA. Cell responses to FGFR3 signalling: growth, differentiation and apoptosis. Exp Cell Res 2005; 304: 417-31.
41. Tomlinson DC, Hurst CD, Knowles MA. Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer. Oncogene 2007; 26: 5889-99.
42. Hernández S, López-Knowles E, Lloreta J et al. Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J Clin Oncol 2006; 24: 3664-71.